| scholarly article | Q13442814 |
| P50 | author | Emilio F. Espejo | Q44026330 |
| Giovanni Marsicano | Q54283626 | ||
| P2093 | author name string | Randy Strong | |
| David A Price | |||
| Beat Lutz | |||
| James L Roberts | |||
| Andrea Giuffrida | |||
| Wouter Koek | |||
| Alexandre Seillier | |||
| Alex A Martinez | |||
| Yolanda Acosta | |||
| P2860 | cites work | Monoamine metabolism and behavioral responses to ethanol in mitochondrial aldehyde dehydrogenase knockout mice | Q27863349 |
| Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure | Q28145614 | ||
| Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains | Q28189423 | ||
| CB1 cannabinoid receptors and on-demand defense against excitotoxicity | Q28207143 | ||
| Identification and functional characterization of brainstem cannabinoid CB2 receptors | Q28276972 | ||
| Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro | Q29144178 | ||
| Parkinson's disease: mechanisms and models | Q29547424 | ||
| Microglia-mediated neurotoxicity: uncovering the molecular mechanisms | Q29547835 | ||
| Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains | Q29616293 | ||
| The endocannabinoid system promotes astroglial differentiation by acting on neural progenitor cells. | Q31031589 | ||
| Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse | Q31863511 | ||
| The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety | Q32133943 | ||
| The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method | Q33589165 | ||
| Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. | Q33845285 | ||
| Endocannabinoids and vascular function. | Q33952765 | ||
| An endogenous cannabinoid (2-AG) is neuroprotective after brain injury | Q34093755 | ||
| Nonpsychotropic cannabinoid receptors regulate microglial cell migration. | Q34179008 | ||
| The role of glial cells in Parkinson's disease | Q34318207 | ||
| Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. | Q34397288 | ||
| Behavioral phenotyping of the MPTP mouse model of Parkinson's disease | Q34420632 | ||
| AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis | Q34539350 | ||
| CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum | Q34605794 | ||
| Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein | Q35025876 | ||
| Cannabinoids and neuroinflammation | Q35046205 | ||
| Neuroinflammatory processes in Parkinson's disease. | Q35094887 | ||
| Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment | Q35111748 | ||
| The role of glial reaction and inflammation in Parkinson's disease. | Q35171038 | ||
| Neuroprotective strategies in Parkinson's disease : an update on progress | Q35182054 | ||
| The MPTP-treated mouse as a model of parkinsonism: how good is it? | Q35282257 | ||
| Neuropathologic features of Parkinson's, Huntington's, and Alzheimer's diseases | Q35346723 | ||
| Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions | Q35634218 | ||
| Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough | Q35751844 | ||
| Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels | Q35765097 | ||
| Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. | Q36248857 | ||
| Treatment of Parkinson's disease : what's on the horizon? | Q36249210 | ||
| Behavioral phenotypes and pharmacology in genetic mouse models of Parkinsonism | Q36581226 | ||
| The endocannabinoid system in targeting inflammatory neurodegenerative diseases | Q36756837 | ||
| Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease | Q36896118 | ||
| Cannabinoids and neuroprotection in basal ganglia disorders. | Q36977766 | ||
| Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway. | Q40677598 | ||
| Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. | Q40743568 | ||
| New stereological methods for counting neurons | Q40843719 | ||
| Cytotoxicity of microglia | Q40870381 | ||
| Induction of interleukin-1 associated with compensatory dopaminergic sprouting in the denervated striatum of young mice: model of aging and neurodegenerative disease. | Q41023740 | ||
| The biodisposition of MPP+ in mouse brain | Q41825025 | ||
| Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 | ||
| Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. | Q43683165 | ||
| Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study | Q43820144 | ||
| Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. | Q43906992 | ||
| The endogenous cannabinoid system controls extinction of aversive memories | Q44085607 | ||
| Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | Q44235386 | ||
| Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease | Q44237885 | ||
| Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism | Q44328472 | ||
| Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. | Q44524201 | ||
| Therapeutic action of cannabinoids in a murine model of multiple sclerosis. | Q45047941 | ||
| CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors. | Q45071453 | ||
| Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity | Q46070812 | ||
| Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. | Q46441823 | ||
| Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease | Q46443478 | ||
| A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease | Q46491157 | ||
| Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. | Q46514030 | ||
| The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells | Q46875092 | ||
| Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: in vitro and in vivo evidence | Q48148192 | ||
| Cannabinoids inhibit sodium-dependent, high-affinity excitatory amino acid transport in cultured rat cortical astrocytes | Q48196162 | ||
| The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse | Q48245374 | ||
| Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures | Q48246173 | ||
| Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties | Q48324018 | ||
| The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. | Q48379589 | ||
| Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). | Q48385796 | ||
| Differences in pre- and post-synaptic sensitivity to apomorphine between saline and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57BL/6 mice as reflected in climbing activity | Q48404095 | ||
| Lowering ambient or core body temperature elevates striatal MPP+ levels and enhances toxicity to dopamine neurons in MPTP-treated mice | Q48450578 | ||
| Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice | Q48600690 | ||
| Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures | Q48963650 | ||
| Microglia: Intrinsic immuneffector cell of the brain | Q56029409 | ||
| Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease | Q56567926 | ||
| The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system | Q58302057 | ||
| [Cannabinoid system and neuroinflammation:therapeutic perspectives in multiple sclerosis] | Q60696495 | ||
| Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model | Q67243728 | ||
| Mechanisms of the inotropic actions of MPTP and MPP+ on isolated atria of rat | Q68055170 | ||
| Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | Q70951248 | ||
| Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo | Q73760293 | ||
| MPTP-induced deficits in motor activity: neuroprotective effects of the spintrapping agent, alpha-phenyl-tert-butyl-nitrone (PBN) | Q74097646 | ||
| Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia | Q74139800 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cannabinoid receptor | Q421237 |
| cannabinoids | Q422936 | ||
| Parkinson's disease | Q11085 | ||
| CNR2 | Q17907844 | ||
| P304 | page(s) | 2177-2186 | |
| P577 | publication date | 2009-05-21 | |
| P1433 | published in | European Journal of Neuroscience | Q5412733 |
| P1476 | title | WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease | |
| P478 | volume | 29 |
| Q47965888 | A cannabinoid type 2 receptor agonist attenuates blood-brain barrier damage and neurodegeneration in a murine model of traumatic brain injury |
| Q34308648 | A synthetic cannabinoid agonist promotes oligodendrogliogenesis during viral encephalitis in rats |
| Q42366580 | AM1241 alleviates MPTP-induced Parkinson's disease and promotes the regeneration of DA neurons in PD mice |
| Q49433973 | Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPARγ receptor |
| Q39075448 | Brain cannabinoid receptor 2: expression, function and modulation |
| Q27324500 | CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease |
| Q35023230 | CB2 receptor agonists protect human dopaminergic neurons against damage from HIV-1 gp120. |
| Q34098185 | CB2: a cannabinoid receptor with an identity crisis |
| Q48105623 | Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series |
| Q47850781 | Cannabinoid CB1 and CB2 Receptors, and Monoacylglycerol Lipase Gene Expression Alterations in the Basal Ganglia of Patients with Parkinson's Disease |
| Q34680801 | Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target. |
| Q38324480 | Cannabinoid Signaling and Neuroinflammatory Diseases: A Melting pot for the Regulation of Brain Immune Responses. |
| Q28277871 | Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's Disease |
| Q36067324 | Cannabinoid modulation of neuroinflammatory disorders. |
| Q52150833 | Cannabinoid receptor type 1 agonist ACEA improves motor recovery and protects neurons in ischemic stroke in mice. |
| Q34591087 | Cannabinoid receptor type-2 stimulation, blockade, and deletion alter the vascular inflammatory responses to traumatic brain injury |
| Q39163671 | Cannabinoid signaling in health and disease |
| Q37734568 | Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. |
| Q36155898 | Cannabinoids and Dementia: A Review of Clinical and Preclinical Data |
| Q38563981 | Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications |
| Q37387247 | Central CB2 receptors in inflammation-driven neurodegeneration: dysregulation and therapeutic potential |
| Q37637769 | Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias |
| Q36343135 | Comparison of the D2 receptor regulation and neurotoxicant susceptibility of nigrostriatal dopamine neurons in wild-type and CB1/CB2 receptor knockout mice |
| Q39527199 | Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer's disease |
| Q92209538 | Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson's Disease |
| Q59798265 | Disordered Peptides Looking for Their Native Environment: Structural Basis of CB1 Endocannabinoid Receptor Binding to Pepcans |
| Q38874824 | Dissecting the Signaling Pathways Involved in the Crosstalk between Metabotropic Glutamate 5 and Cannabinoid Type 1 Receptors |
| Q27335848 | Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease |
| Q35645037 | Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation |
| Q38018946 | Endocannabinoid modulation of dopaminergic motor circuits. |
| Q89741164 | Endocannabinoid receptors in the CNS: potential drug targets for the prevention and treatment of neurologic and psychiatric disorders |
| Q39368845 | Endocannabinoid system in neurodegenerative disorders. |
| Q34352311 | Endocannabinoids Prevent β-Amyloid-mediated Lysosomal Destabilization in Cultured Neurons |
| Q38593124 | Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others |
| Q40112882 | Endocannabinoids exert CB1 receptor-mediated neuroprotective effects in models of neuronal damage induced by HIV-1 Tat protein |
| Q28075692 | Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents |
| Q27316448 | Expression Analysis of CB2-GFP BAC Transgenic Mice |
| Q48336830 | Hypoxia induces microglia autophagy and neural inflammation injury in focal cerebral ischemia model |
| Q37919370 | Immunomodulatory properties of kappa opioids and synthetic cannabinoids in HIV-1 neuropathogenesis |
| Q35028750 | Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS |
| Q33751118 | In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability |
| Q43162071 | Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease |
| Q93078709 | Involvement of CB2 Receptors in the Neurobehavioral Effects of Catha Edulis (Vahl) Endl. (Khat) in Mice |
| Q64781374 | Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms? |
| Q24633122 | Is lipid signaling through cannabinoid 2 receptors part of a protective system? |
| Q46926746 | Let's make microglia great again in neurodegenerative disorders. |
| Q36861976 | Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat. |
| Q37512670 | Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy. |
| Q92882814 | Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson's Disease |
| Q36933683 | Modulating the endocannabinoid system in human health and disease--successes and failures |
| Q38684679 | Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation |
| Q38874674 | Neuroprotective Effect of JZL184 in MPP(+)-Treated SH-SY5Y Cells Through CB2 Receptors |
| Q47868304 | Neuroprotective Effects of Filgrastim in Rotenone-Induced Parkinson's Disease in Rats: Insights into its Anti-Inflammatory, Neurotrophic, and Antiapoptotic Effects |
| Q42366868 | Neuroprotective Effects of β-Caryophyllene against Dopaminergic Neuron Injury in a Murine Model of Parkinson's Disease Induced by MPTP |
| Q41678707 | Neurotransmitter receptors on microglia |
| Q36074595 | New insights on endocannabinoid transmission in psychomotor disorders |
| Q41502987 | Orchestrated activation of mGluR5 and CB1 promotes neuroprotection |
| Q38771463 | PET imaging of cannabinoid type 2 receptors with [11C]A-836339 did not evidence changes following neuroinflammation in rats |
| Q97524620 | Potential pharmacological approaches for the treatment of HIV-1 associated neurocognitive disorders |
| Q37082410 | Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors |
| Q35499568 | Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection |
| Q37872326 | Prospects for cannabinoid therapies in basal ganglia disorders |
| Q47432979 | Radioligands for positron emission tomography imaging of cannabinoid type 2 receptor. |
| Q28260273 | Recent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiology |
| Q42102522 | Regulation of Fas receptor/Fas-associated protein with death domain apoptotic complex and associated signalling systems by cannabinoid receptors in the mouse brain. |
| Q35193305 | Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease |
| Q28073952 | Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders |
| Q39392775 | Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson's Disease |
| Q46871693 | Tetramethylpyrazine Ameliorates Rotenone-Induced Parkinson's Disease in Rats: Involvement of Its Anti-Inflammatory and Anti-Apoptotic Actions. |
| Q33908169 | The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products |
| Q42495608 | The bright side of psychoactive substances: cannabinoid-based drugs in motor diseases. |
| Q42701971 | The emerging role of PET imaging in dementia. |
| Q36130163 | The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation |
| Q100464821 | The impact of cannabinoid type 2 receptors (CB2Rs) in neuroprotection against neurological disorders |
| Q38072364 | The neuroprotective role of endocannabinoids against chemical-induced injury and other adverse effects |
| Q35171113 | The therapeutic potential of cannabinoids for movement disorders |
| Q26991513 | Therapeutic potential of monoacylglycerol lipase inhibitors |
| Q37508349 | TracMouse: A computer aided movement analysis script for the mouse inverted horizontal grid test |
| Q48355383 | URB597 and the Cannabinoid WIN55,212-2 Reduce Behavioral and Neurochemical Deficits Induced by MPTP in Mice: Possible Role of Redox Modulation and NMDA Receptors |
| Q43441791 | Whole-body biodistribution and radiation dosimetry of the cannabinoid type 2 receptor ligand [11C]-NE40 in healthy subjects |
| Q42500348 | Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease. |
Search more.